April 25, 2005
New technology unveiled for breast cancerTopics: Medical Science News
PHOENIX, Apr 25, 2005 (United Press International via COMTEX) -- A new test technology called MammaPrint that analyzes patients' breast tumors for individual DNA profiles was unveiled in Phoenix Monday.
"MammaPrint more accurately distinguishes between lymph node-negative breast cancer patients who would benefit from additional therapy from those who would not, helping oncologists offer more effective therapy to their patients," said Dr. Robert Penny, the president and chief executive officer of the Molecular Profiling Institute.
The National Cancer Institute of the National Institutes of Health said 216,000 new cases of breast cancer are found annually in the United States of which 24,200 will develop distant metastases and require further treatment. However, in node-negative women under 51 years of age, 45 percent are treated with chemotherapy in the United States today, meaning more than twice as many patients are currently treated than may actually need the therapy.
The 70 genes in a tumor analyzed by MammaPrint predict the 10-year survival of the patient at a significance level over three times greater than existing methods and with an accuracy level of 96.7 percent as determined by a study published in the New England Journal of Medicine.
Breast cancer: different in each patient
Posted by Richard at April 25, 2005 12:00 PM
Articles Related to Medical Science News: